心筋縮性心筋症患者の短期発症率と心筋縮性心筋縮症患者の短期発症率と心筋縮性心筋縮性心筋縮性心筋縮性心筋縮性心筋縮性心筋縮性心筋縮性心筋縮性心筋縮性心筋縮性心筋縮性心筋縮性心筋縮性心筋縮性心筋縮性心筋縮性心筋縮性心筋縮性心筋縮性心筋縮性心筋縮性心筋縮性心筋縮性心筋縮性心筋縮性心筋
PubMedで要約を見る
まとめ
この要約は機械生成です。心筋縮性心筋病 (HCM) の患者では,心筋縮性心筋縮症 (AF) のリスクを増加させない. RCTのメタ解析では,CMIの使用でAFの有意な増加は示されなかった.
科学分野
- 心臓病科
- 薬理学について
- 臨床試験
背景
- 心房細動 (AF) は,多動性心筋病 (HCM) の一般的な重篤な不律です.
- 心筋ミオシン阻害剤 (CMI) は,阻害性HCMの新興治療法である.
- HCM患者におけるAF発生率に対するCMIの影響については,相反するデータがある.
研究 の 目的
- 心筋縮症 (HCM) の患者の心筋縮症 (AF) の新規発症リスクを評価する.
- HCMにおけるCMI治療に関連したAF発生に関する現在の証拠をまとめます.
主な方法
- 2025年3月までRCTと観察研究のためのMEDLINE,Embase,Cochrane CENTRALの体系的な文献検索
- 6つのRCT (826人の参加者) のメタアナリシスで,CMIとプラセボを比較して,新規発症したAFのプライマリエンドポイントを決定した.
- RCTと観察研究から集約されたAF発生率の計算.
主要な成果
- RCTでは,CMIの使用でプラセボと比較してAFの発生リスクは増加しなかった (RR1. 06; 95% CI: 0. 55- 2. 06).
- RCTにおけるAPの集団発生率は,CMIで100人当たり4. 3であった.
- 観察研究におけるAPの総発生率は100人当たり5. 2であった.
結論
- 心筋ミオシン阻害剤の使用は,RCTデータに基づいて,HCM患者におけるAFのリスク増加と関連していません.
- 観察研究と比較したRCTではAFの発生率が低かった.
- HCMにおけるCMIのAFに対する長期的な影響を理解するには,さらなる研究が必要である.
関連する概念動画
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...

